ARBITER 3 Trial
From Wikidoc - Reading time: 3 min
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
ARBITER 3 Trial On the Web |
|
American Roentgen Ray Society Images of ARBITER 3 Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective[edit | edit source]
To study the effects of long term treatment with extended release niacin (ERN) on HDL levels and carotid intima- media thickness in patients who participated in ARBITER 2.
Methods[edit | edit source]
88% (149) of patients enrolled in the ARBITER trial participated in the ARBITER 3 trial, those who either were continued or crossed over to the placebo group. The long term effects of ERN on HDL cholesterol and carotid intima- media thickness were examined during 12- 24 months of treatment.
Results[edit | edit source]
- The ERN group showed an increase in HDL-C levels along with modest reductions in LDL-C and triglycerides.
- A net regression in CMIT was seen in patients treated with ENC for 12 months.
- An additional regression was noted in patients treated with ENC for 24 months.
- Changes in HDL-C were independently associated with regression of CIMT, controlling for changes in LDL and triglycerides.
Conclusion[edit | edit source]
ERN when added to statin therapy significantly increases HDL levels and induces atherosclerosis regression. Open label design and the inability to correlate CIMT effects to clinical outcomes were the limitations of this study.[1]
References[edit | edit source]
- ↑ Taylor AJ, Lee HJ, Sullenberger LE (2006). "The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3". Current Medical Research and Opinion. 22 (11): 2243–50. doi:10.1185/030079906X148508. PMID 17076985. Unknown parameter
|month=ignored (help)
EncycloReader
is supported by the 
KSF